Velpatasvir

Velpatasvir
Clinical data
Trade names	Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir)
Routes of; administration	Oral (tablets)
ATC code	J05AP55 (WHO) (combination with sofosbuvir); J05AP56 (WHO) (combination with sofosbuvir and voxilaprevir);
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	>99.5%
Metabolism	Liver (CYP2B6, 2C8, 3A4)
Elimination half-life	15 hours
Excretion	Feces (94%), urine (0.4%)
Identifiers
	IUPAC name Methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate;
CAS Number	1377049-84-7;
PubChem CID	67683363;
DrugBank	DB11613;
ChemSpider	34501056;
UNII	KCU0C7RS7Z;
KEGG	D10806;
ChEBI	CHEBI:133009 ;
CompTox Dashboard (EPA)	DTXSID70722565 ;
Chemical and physical data
Formula	C49H54N8O8
Molar mass	883.019 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)nc65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1;
	InChI InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1; Key:FHCUMDQMBHQXKK-CDIODLITSA-N;

Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.^[2]^[3]

^ "Epclusa (sofosbuvir and velpatasvir) Tablets, for Oral Use. Full Prescribing Information" (PDF). Gilead Sciences, Inc. Foster City, CA 94404. Retrieved 1 August 2016.
^ "FDA Approves Epclusa". Drugs.com.
^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556.

[PrescribingInfo-1] "Epclusa (sofosbuvir and velpatasvir) Tablets, for Oral Use. Full Prescribing Information" (PDF). Gilead Sciences, Inc. Foster City, CA 94404. Retrieved 1 August 2016.

[2] "FDA Approves Epclusa". Drugs.com.

[pmid29546556-3] Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556.

[1]

[2]

[3]